Meanwhile, VaxInnate plans to pursue clinical development and licensure of pandemic and seasonal flu vaccines in the United States. In 2009, VaxInnate conducted successful clinical trials evaluating the potency, efficacy and safety of the vaccine using the Solomon Islands seasonal influenza strain of the H1N1 flu. VaxInnate ™s pandemic H1N1 flu vaccine is expected to enter clinical development in the United States this year.

VaxInnate is pleased to partner with Biological E. to meet the H1N1 vaccine needs of India and to demonstrate the speed and volume capabilities of our proprietary vaccine technology, said Alan Shaw, PhD, President and CEO of VaxInnate. We will continue to pursue domestic and other international partnerships for development of this and other vaccines to meet global needs.

VaxInnate ™s proprietary technology -- based upon a combination of toll-like receptor-mediated (TLR) immune enhancement and recombinant bacterial production of vaccine antigen -- conveys significant speed and volume advantages, making it capable of producing hundreds of millions of vaccine doses in weeks instead of months.

Source: VaxInnate